Big Pharma

Trump threatens 100% tariff hike on pharma imports into the US
26 September 2025   Sweeping tariffs send shockwaves through the pharma sector, as experts warn of consumer detriment and supply chain risks.

Latest Features

Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
All features


More News

17 September 2025   A notable Ninth Circuit ruling raises questions about disclosure that trade secrets plaintiffs will want to consider—particularly with regards to timing, says Carolyn Hoecker Luedtke of Munger, Tolles & Olson.
16 September 2025   From drug discovery to post-market surveillance, AI is rewriting the rules in pharma—and the patent system is struggling to keep up. At AIPPI’s World Congress 2025, Marisa Woutersen hears experts debate AI disclosure, inventive step, and inventorship.
11 September 2025   Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment.
9 September 2025   Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen.
5 September 2025   The UK pharma giant has opened a new front in its global litigation strategy involving Moderna, Pfizer, and BioNTech.
4 September 2025   The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.
28 August 2025   A high number of filings from China has driven patent applications up by nearly a third at Ireland’s intellectual property office, which also reported a rise in SPC applications and strong activity in the medtech sector.
More news